We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients.
- Authors
Avivi, Irit; Shragai, Tamir; Luttwak, Efrat; Trestman, Svetlana; Cohen, Yael C.
- Abstract
Objectives: To evaluate whether low‐dose belantamab mafodotin (B‐MAF) dosing results in lower toxicity and better overall outcome. Methods: We retrospectively evaluated nine consecutive patients treated with low‐dose (1.9 mg/kg) B‐MAF. Results: The median age was 70 years. Most patients were penta‐refractory. Ocular toxicity was observed in 77.7%. Adverse events resulting in treatment delays were recorded in 9 out of 124 cycles being given. Overall response rate was 66% (6/9), and all responding patients achieved very good partial response or better. Within a median follow‐up of 12 (range 0.5–13.8) months, median progression‐free survival and overall survival were 14 (CI95% 6–22) and 20 (95%CI 0–41) months, respectively. Conclusion: Low‐dose B‐MAF regimen showed high‐efficacy and low‐toxicity profile.
- Subjects
MULTIPLE myeloma; OCULAR toxicology; PROGRESSION-free survival; OVERALL survival; TREATMENT delay (Medicine)
- Publication
European Journal of Haematology, 2024, Vol 112, Issue 3, p367
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.14120